SeekingAlpha · Jan 26, 2026
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026
Rigel Pharma (RIGL) outlook: Tavalisse boosts net income, valuation and cash; R289 MDS data a 2026 catalyst.
RI
NASDAQ · RIGL
Rigel Pharmaceuticals, Inc.
Healthcare · Biotechnology
$46.48
Up+$0.35 (+0.75%)
Updated Aug 27, 2026, 4:34 PM
SID Score
6.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 751.68M
- P/E ratio
- 6.71
- Dividend yield
- 0.00%
- 52-week range
- $24.95 – $52.24
- Volume
- 232.25K
- Avg. volume
- 631.51K
Price performance
RIGL price history
1M range · 21 trading sessions · Daily adjusted prices
RIGL closed at $46.48 after 21 trading sessions, up 18.97% for the selected period.
- Last close
- $46.48
- Period change
- +18.97%
- Period low
- $36.81
- Period high
- $46.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 26, 2026 | $46.34 | $47.09 | $45.365 | $46.48 | 232.25K |
| Aug 25, 2026 | $45.48 | $47.46 | $45.14 | $46.75 | 373.97K |
| Aug 24, 2026 | $45.63 | $46.21 | $44.505 | $45.11 | 542.01K |
| Aug 21, 2026 | $45.74 | $46.4925 | $45.00 | $45.89 | 322.09K |
| Aug 20, 2026 | $46.24 | $47.34 | $44.795 | $45.25 | 417.41K |
| Aug 19, 2026 | $44.02 | $47.25 | $44.00 | $46.96 | 515.83K |
| Aug 18, 2026 | $42.31 | $43.71 | $41.3701 | $43.62 | 267.32K |
| Aug 17, 2026 | $42.90 | $43.26 | $42.08 | $42.45 | 502.5K |
| Aug 14, 2026 | $41.41 | $42.69 | $40.5433 | $42.58 | 224.04K |
| Aug 13, 2026 | $42.52 | $42.60 | $40.32 | $40.79 | 265.33K |
| Aug 12, 2026 | $42.00 | $42.99 | $41.50 | $41.87 | 335.55K |
| Aug 11, 2026 | $41.37 | $42.04 | $40.95 | $42.02 | 208.36K |
| Aug 10, 2026 | $39.96 | $41.79 | $39.90 | $41.66 | 230.34K |
| Aug 7, 2026 | $39.55 | $41.13 | $39.5107 | $40.17 | 315.51K |
| Aug 6, 2026 | $39.85 | $41.24 | $38.46 | $39.22 | 480.96K |
| Aug 5, 2026 | $42.48 | $43.49 | $38.18 | $40.48 | 748.88K |
| Aug 4, 2026 | $37.94 | $39.45 | $37.70 | $38.70 | 334.13K |
| Aug 3, 2026 | $36.96 | $37.54 | $36.44 | $37.43 | 187.28K |
| Jul 31, 2026 | $37.63 | $37.825 | $36.14 | $36.81 | 175.02K |
| Jul 30, 2026 | $38.51 | $39.015 | $37.2605 | $38.06 | 216.11K |
| Jul 29, 2026 | $38.58 | $39.95 | $37.95 | $39.07 | 223.4K |
Latest RIGL news
The latest Smart Investors Daily articles mentioning RIGL.
Stock researchCompany · Overview
RIGL research
Overview
Company profile and research snapshot.
Company profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $40.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | Neutral | — |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | — |
| May 27, 2026 | HC Wainwright & Co. | Buy | — |
| May 22, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 15, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rigel Pharmaceuticals, Inc. (RIGL) 44th Annual J.P.
SeekingAlpha · Jan 1, 2026
Rigel Pharma: Formulating A Game Plan For 2026
prnewswire.com · Dec 7, 2025
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose group SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS).
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
